Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This role represents a unique opportunity to serve as a strategic and scientific leader within Cancer Immunology, reporting into the Biology organization. We are seeking a highly motivated, critical thinker with a passion for scientific excellence and innovation, who can drive the discovery and advancement of novel immuno-oncology targets and modalities. The successful candidate will lead a multidisciplinary team, shape the scientific vision for Discovery Cancer Immunology, and provide oversight of scientific integration across both Discovery and Translational Cancer Immunology. As a strategic and scientific leader in Cancer Immunology, you will report into the Vice President and Head of Cancer Immunology.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree
Number of Employees
251-500 employees